Title : Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.

Pub. Date : 2017 Apr

PMID : 28259610






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Vandetanib is a novel tyrosine kinase inhibitor of VEGFR2, RET, and EGFR, all of which are in involved in the pathogenesis of pancreatic cancer. vandetanib kinase insert domain receptor Homo sapiens